PinnedTechBio KPIs: Is Your Discovery Platform Validated?Pablo Lubroth is an investor at Hummingbird Ventures, a global early stage fund, where he covers bio + health. Viswa Colluru is the Founder…Apr 5, 2022Apr 5, 2022
PinnedDefensibility Through Execution: Building the Next Generation of Bio PlatformsPablo Lubroth and Xinchen WangFeb 14, 2022Feb 14, 2022
In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the…By Pablo Lubroth, Gaia Colasante and Gabriele LignaniFeb 25, 2021Feb 25, 2021
Can We Predict Drug Efficacy with Artificial Intelligence?By Jeanne-Françoise Williamson D.Phil, CEO, Williamson Biotech Solutions and Pablo Lubroth, University of Cambridge, MPhil Bioscience…Oct 17, 2017Oct 17, 2017
London Psychotropics: Restrictions on Classified Drugs, A Research PerspectiveLondon Psychotropics is a novel group for neuroscientists of all levels and career backgrounds interested in drugs and the brain. The…Feb 16, 2016Feb 16, 2016
